Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Methylation of the p16INK4a promoter region in telomerase immortalized human keratinocytes co-cultured with feeder cells

Abstract

Human keratinocytes grown in co-culture with fibroblast feeder cells have an extended in vitro lifespan and delayed accumulation of the tumor suppressor protein p16INK4a when compared to the same cells grown on tissue culture plastic alone. Previous studies have indicated that human keratinocytes can be immortalized by telomerase activity alone when grown in co-culture with feeder cells, suggesting that loss of the p16INK4a/Rb pathway is not required for immortalization. Using two independent human keratinocyte cell strains, we found that exogenous telomerase expression and co-culture with feeder cells results in efficient extension of lifespan without an apparent crisis. However, when these cells were transferred from the co-culture environment to plastic alone they experienced only a brief period of slowed growth before continuing to proliferate indefinitely. Examination of immortal cell lines demonstrated p16INK4a promoter methylation had occurred in both the absence and presence of feeder cells. Reintroduction of p16INK4a into immortal cell lines resulted in rapid growth arrest. Our results suggest that p16INK4a/Rb-induced telomere-independent senescence, although delayed in the presence of feeders, still provides a proliferation barrier to human keratinocytes in this culture system and that extended culture of telomerase-transduced keratinocytes on feeders can lead to the methylation of p16INK4a.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

References

  • Baek JH, Lee G, Kim SN, Kim JM, Kim M, Chung SC et al. (2003). Int J Mol Med 12: 319–325.

  • Blanton RA, Perez-Reyes N, Merrick DT, McDougall JK . (1991). Am J Pathol 138: 673–685.

  • Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. (1998). Science 279: 349–352.

  • Brenner AJ, Stampfer MR, Aldaz CM . (1998). Oncogene 17: 199–205.

  • Chakravarti A, Heydon K, Wu CL, Hammond E, Pollack A, Roach M et al. (2003). J Clin Oncol 21: 3328–3334.

  • Cody 2nd DT, Huang Y, Darby CJ, Johnson GK, Domann FE . (1999). Oral Oncol 35: 516–522.

  • Curtis CD, Goggins M . (2005). Methods Mol Med 103: 123–136.

  • Darbro BW, Schneider GB, Klingelhutz AJ . (2005). J Invest Dermatol 125: 499–509.

  • Das PM, Singal R . (2004). J Clin Oncol 22: 4632–4642.

  • Der CJ, Pan BT, Cooper GM . (1986). Mol Cell Biol 6: 3291–3294.

  • Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA et al. (2000). Mol Cell Biol 20: 1436–1447.

  • Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR et al. (2001). J Clin Oncol 19: 299–304.

  • Farwell DG, Shera KA, Koop JI, Bonnet GA, Matthews CP, Reuther GW et al. (2000). Am J Pathol 156: 1537–1547.

  • Foster SA, Demers GW, Etscheid BG, Galloway DA . (1994). J Virol 68: 5698–5705.

  • Foster SA, Galloway DA . (1996). Oncogene 12: 1773–1779.

  • Fu B, Quintero J, Baker CC . (2003). Cancer Res 63: 7815–7824.

  • Govindarajan B, Klafter R, Miller MS, Mansur C, Mizesko M, Bai X et al. (2002). Mol Med 8: 1–8.

  • Groeger AM, Caputi M, Esposito V, De Luca A, Bagella L, Pacilio C et al. (1999). J Thorac Cardiovasc Surg 118: 529–535.

  • Harada H, Nakagawa H, Oyama K, Takaoka M, Andl CD, Jacobmeier B et al. (2003). Mol Cancer Res 1: 729–738.

  • Herbert BS, Wright WE, Shay JW . (2002). Oncogene 21: 7897–7900.

  • Herman JG, Baylin SB . (2003). N Engl J Med 349: 2042–2054.

  • Jacobs JJ, de Lange T . (2004). Curr Biol 14: 2302–2308.

  • Jarmalaite S, Kannio A, Anttila S, Lazutka JR, Husgafvel-Pursiainen K . (2003). Int J Cancer 106: 913–918.

  • Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H et al. (1999). Cancer Res 59: 2957–2964.

  • Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R et al. (2001). Am J Pathol 159: 1613–1617.

  • Kang MK, Kameta A, Shin KH, Baluda MA, Kim HR, Park NH . (2003). Exp Cell Res 287: 272–281.

  • Kang MK, Kameta A, Shin KH, Baluda MA, Park NH . (2004). J Cell Physiol 199: 364–370.

  • Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ . (1998). Nature 396: 84–88.

  • Klingelhutz AJ, Qian Q, Phillips SL, Gourronc FA, Darbro BW, Patil SR . (2005). Virology 340: 237–244.

  • Korkolopoulou P, Christodoulou P, Lazaris A, Thomas-Tsagli E, Kapralos P, Papanikolaou A et al. (2001). Eur Urol 39: 167–177.

  • Lewis A, Mitsuya K, Umlauf D, Smith P, Dean W, Walter J et al. (2004). Nat Genet 36: 1291–1295.

  • Liggett Jr WH, Sidransky D . (1998). J Clin Oncol 16: 1197–1206.

  • Liu L, Zhang J, Bates S, Li JJ, Peehl DM, Rhim JS et al. (2005). Int J Oncol 26: 275–285.

  • Momparler RL . (2003). Oncogene 22: 6479–6483.

  • Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG . (2003). Am J Pathol 163: 477–491.

  • Nilsson K, Svensson S, Landberg G . (2004). Mod Pathol 17: 1464–1474.

  • Noble JR, Zhong ZH, Neumann AA, Melki JR, Clark SJ, Reddel RR . (2004). Oncogene 23: 3116–3121.

  • Partridge M, Gaballah K, Huang X . (2005). Cancer Metastasis Rev 24: 71–85.

  • Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG et al. (2003). Cancer Res 63: 1114–1121.

  • Puthenveettil JA, Burger MS, Reznikoff CA . (1999). Adv Exp Med Biol 462: 83–91.

  • Ramirez RD, Herbert BS, Vaughan MB, Zou Y, Gandia K, Morales CP et al. (2003). Oncogene 22: 433–444.

  • Ramirez RD, Morales CP, Herbert BS, Rohde JM, Passons C, Shay JW et al. (2001). Genes Dev 15: 398–403.

  • Reznikoff CA, Loretz LJ, Pesciotta DM, Oberley TD, Ignjatovic MM . (1987). J Cell Physiol 131: 285–301.

  • Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM . (1996). Cancer Res 56: 2886–2890.

  • Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H et al. (2002). Mol Cell Biol 22: 5157–5172.

  • Rocco JW, Sidransky D . (2001). Exp Cell Res 264: 42–55.

  • Romanenko A, Morell-Quadreny L, Lopez-Guerrero JA, Pellin A, Nepomnyaschy V, Vozianov A et al. (2002). Diagn Mol Pathol 11: 163–169.

  • Sandhu C, Peehl DM, Slingerland J . (2000). Cancer Res 60: 2616–2622.

  • Sharpless NE . (2005). Mutat Res 576: 22–38.

  • Stampfer MR, Garbe J, Levine G, Lichtsteiner S, Vasserot AP, Yaswen P . (2001). Proc Natl Acad Sci USA 98: 4498–4503.

  • Stampfer MR, Yaswen P . (2003). Cancer Lett 194: 199–208.

  • Svensson S, Nilsson K, Ringberg A, Landberg G . (2003). Cancer Res 63: 1737–1742.

  • Taylor LM, James A, Schuller CE, Brce J, Lock RB, Mackenzie KL . (2004). J Biol Chem 279: 43634–43645.

  • Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF . (2003). Ann NY Acad Sci 983: 84–100.

  • Timmermann S, Hinds PW, Munger K . (1998). Oncogene 17: 3445–3453.

  • Tsihlias J, Kapusta L, Slingerland J . (1999). Annu Rev Med 50: 401–423.

  • Tsutsui T, Kumakura S, Yamamoto A, Kanai H, Tamura Y, Kato T et al. (2002). Carcinogenesis 23: 2111–2117.

  • Wang J, Hannon GJ, Beach DH . (2000). Nature 405: 755–756.

  • Wege H, Chui MS, Le HT, Tran JM, Zern MA . (2003). Nucleic Acids Res 31: E3–E3.

  • Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Sasaki C et al. (2004). Clin Cancer Res 10: 5684–5691.

  • Whitehead I, Kirk H, Kay R . (1995). Mol Cell Biol 15: 704–710.

  • Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ . (1997). Cancer Res 57: 2619–2622.

  • Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A et al. (1999). J Biol Chem 274: 26141–26148.

  • Zhao W, Soejima H, Higashimoto K, Nakagawachi T, Urano T, Kudo S et al. (2005). J Biochem (Tokyo) 137: 431–440.

  • Zohn IE, Symons M, Chrzanowska-Wodnicka M, Westwick JK, Der CJ . (1998). Mol Cell Biol 18: 1225–1235.

  • Zongaro S, de Stanchina E, Colombo T, D'Incalci M, Giulotto E, Mondello C . (2005). Cancer Res 65: 11411–11418.

Download references

Acknowledgements

We thank Robert Weinberg for providing the TERT-neo and TERT-hygro retroviral constructs, Denise Galloway for providing the pLXSH retroviral construct, and Francoise Gourronc for providing the p16-Bluescript vector, as well as Joseph Zabner for the use of his immunofluorescent microscope, Shiva Patil for assistance with cytogenetic analysis, and members of the Frederick Domann laboratory for help with bisulfite sequencing protocols. We are grateful to the other members of the Klingelhutz laboratory for helpful discussions. This work was supported by a grant to AJK from the National Institute on Aging (NIA), R01 AG18265 and a grant from the National Cancer Institute (NCI), R01 CA73612 to FED. Benjamin Darbro was supported by training grants from the National Heart, Lung, and Blood Institute (NHLBI), T32 HL07638, and the University of Iowa Medical Scientist Training Program (MSTP), T32 GM07337.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A J Klingelhutz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Darbro, B., Lee, K., Nguyen, N. et al. Methylation of the p16INK4a promoter region in telomerase immortalized human keratinocytes co-cultured with feeder cells. Oncogene 25, 7421–7433 (2006). https://doi.org/10.1038/sj.onc.1209729

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209729

Keywords

  • hTERT
  • CDKN2A
  • senescence
  • epigenetic
  • Rb
  • telomeres

Further reading

Search

Quick links